je.st
news
Tag: clinical
Lumenis Announces UltraPulse with SCAAR FX Clinical Data to be Presented at the 16th European Burns Association Congress
2015-09-21 12:31:21| Industrial Newsroom - All News for Today
Lumenis Ltd. (NASDAQ: LMNS), the world's largest energy-based medical device company for aesthetic, surgical, and ophthalmic applications, announced today that two oral presentations showing the benefit of the UltraPulse in the treatment of patients with severe burn injuries will be presented at the 16th European...
Tags: data
presented
association
european
PharmaCyte Biotech Discusses Major Milestones Ahead of Phase 2b Clinical Trial in Pancreatic Cancer
2015-09-15 15:58:58| Biotech - Topix.net
PharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-BoxA , discussed today some of the major "milestone" tasks that must be completed to begin its Phase 2b clinical trial in pancreatic cancer. The trial will test the effectiveness and safety of PharmaCyte Biotech's pancreatic cancer treatment.
VA Spinal Cord Injury Center Demonstrates Clinical Improvement with the EarlySense Monitoring System
2015-09-14 12:31:15| Industrial Newsroom - All News for Today
Data presented at ASCIP Educational Conference WALTHAM, Massachusetts, - A VA Spinal Cord Injury (SCI) Center has reported significant positive clinical results achieved with the EarlySense Monitoring System. The Scientific Poster was presented at the Academy of Spinal Cord Injury Professionals (ASCIP) 2015...
Tags: system
center
improvement
monitoring
RedHill Biopharma - 9 Late Stage Clinical Assets, $150 Million Market Cap - Is It Undervalued?
2015-09-11 14:41:16| Biotech - Topix.net
Every market day, we select up to 20 of our authors' top long and short ideas, exclusively for PRO subscribers. RedHill focuses on late stage oral gastrointestinal drugs; the company has two potential blockbusters in Phase 3 studies, 9 active clinical programs in total.
DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on...
2015-09-10 15:12:57| Logistics - Topix.net
DelMar Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today presented updated clinical data from its Phase I/II study of lead product candidate VAL-083 , in patients with refractory glioblastoma multiforme , at GBM2015 : 2 International Symposium on Clinical and Basic Investigation in Glioblastoma in Toledo, Spain. The Company's data was presented in a poster entitled, "Update on Phase I/II study of VAL-083 in patients with recurrent malignant glioma."
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] next »